Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00844207 | A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine | PHASE1 | COMPLETED | 40 | — | — | Feb 1, 2009 | Apr 1, 2009 | Apr 21, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base. |
| Treatment B | ACTIVE_COMPARATOR | A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base. |
| Name | Type | Description |
|---|---|---|
| Fixed combination of Azithromycin and Chloroquine | DRUG | Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose. |
| Azithromycin and Chloroquine | DRUG | Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose. |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, Primaquine, Chloroquine, GSK3772701, RTS,S/AS01E vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |